Neuropeptides involved in the pathophysiology of schizophrenia and major depression (Q35130197)

6 August 2017

Neuropeptides involved in the pathophysiology of schizophrenia and major depression (English)

1 reference

6 August 2017

0 references

1 reference

David De Wied

1

1 reference

6 August 2017

Hein O. Sigling

series ordinal

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12754159

3 January 2024

publication date

1 August 2002

1 reference

full work available at URL

6 August 2017

http://www.springerlink.com/index/pdf/10.1080/10298420290031432

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

3 January 2024

published in

Neurotoxicity Research

1 reference

6 August 2017

4

1 reference

6 August 2017

5-6

1 reference

6 August 2017

453-468

1 reference

https://scigraph.springernature.com/pub.10.1080/10298420290031432

6 August 2017

0 references

cites work

Low levels of somatostatin in human CSF mark depressive episodes

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Elevated CSF CRF in suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The role of corticotropin-releasing factor in depression and anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

21 January 2018

Myxoedematous madness

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid neuropeptides in mood disorder and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cloning of human neurotensin/neuromedin N genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF substance P immunoreactivity in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid neuropeptide Y in depression and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Endorphins: Profound Behavioral Effects in Rats Suggest New Etiological Factors in Mental Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The biochemistry of affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cholecystokinin-dopamine interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Role of corticotropin-releasing factor, vasopressin and the autonomic nervous system in learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuroleptic activity of the neuropeptide β-LPH62–77 ([Des-Tyr1]γ-endorphin; DTγE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Glucocorticoids and the genesis of depressive illness. A psychobiological model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Thyroid axis activity and serotonin function in major depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Lack of correlation between cerebrospinal fluid thyrotropin-releasing hormone (TRH) and TRH-stimulated thyroid-stimulating hormone in patients with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Influence of substance P and fragments on passive avoidance behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Review: thyroid function in psychiatric illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Depression in Parkinson's disease is not accompanied by more corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Corticotropin-releasing factor binding sites in cortex of depressed suicides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The thyroid axis and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The C-Fragment of β-Lipotropin: An Endogenous Neuroleptic or Antipsychotogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Corticotropin-releasing hormone in depression and post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Consistent reduction of ACTH responses to stimulation with CRH, vasopressin and hypoglycaemia in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neurotensin: an endogenous antipsychotic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptides in human brain--postmortem studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal Fluid Immunoreactive Cortieotropin-Releasing Hormone and Adrenocorticotropin Secretion in Cushing's Disease and Major Depression: Potential Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

High-dose destyrosine-?-endorphin in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

[3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Plasmatic vasopressin neurophysin in depression: basic levels and relations with HPA axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Identification of a vasopressin-neurophysin and of an oxytocin-neurophysin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Specificity of hypothalamic peptides in the control of behavioral and physiological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Correlation between vasopressin baseline and TSH-blunting in depressives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced CSF neurotensin concentration in drug-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Extrapituitary expression of the rat V1b vasopressin receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neurotensin analogs indications for use as potential antipsychotic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Inadequate treatment response to des-enkephalin-gamma-endorphin compared with thioridazine and placebo in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Regional Brain Concentrations of Neuropeptides in Huntington's Chorea and Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced density of striatal somatostatin receptors in Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Behavioral Effects of Hypothalamic Releasing Hormones in Animals and Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Peptides, the limbic lobe and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Topography and characteristics of specific binding sites for non-opioid gamma-type endorphins in the rat brain as studied by autoradiography with [35S]Met-desenkephalin-gamma-endorphin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF corticotropin-releasing hormone in depressed patients and normal control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: negative findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF Somatostatin in Affective Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Plasmatic somatostatin as a marker of positive symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

A heuristic model of mental depression derived from basic and applied research on thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Antidepressant-like effect of brain-derived neurotrophic factor (BDNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid vasopressin in neurological and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Morning and evening TSH response to TRH and sleep EEG disturbances in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Glucocorticoids and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Plasma levels of arginine vasopressin elevated in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Improvement of Schizophrenic Patients Treated With Des-Tyr1]-γ-endorphin (DTγE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Reduced neuropeptide Y concentrations in suicide brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Treatment of depression with antiglucocorticoid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Effect of lysine vasopressin in depressed patients on mood and 24-hour rhythm of growth hormone, cortisol, melatonin and prolactin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The high affinity neurotensin receptor gene (NTSR1): comparative sequencing and association studies in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

The Effects of Ceruletide in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Comparative sequencing of the proneurotensin gene and association studies in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10298420290031432

Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report

21 January 2018

1 reference

12 December 2020

A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results

1 reference

12 December 2020

Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity

1 reference

12 December 2020

Effect of (des-tyr)-gamma-endorphin in schizophrenia

1 reference

12 December 2020

Neuropeptide gene polymorphisms in affective disorder and schizophrenia

1 reference

12 December 2020

Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders

1 reference

12 December 2020

Plasma neuropeptide Y in patients with major depressive disorder

1 reference

12 December 2020

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

1 reference

12 December 2020

Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans

1 reference

12 December 2020

Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex

1 reference

12 December 2020

Differential responses of identified rat hypothalamic paraventricular neurons to suprachiasmatic nucleus stimulation

1 reference

12 December 2020

Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt

1 reference

12 December 2020

[Central transmission of afferent impulses. III. Incidence and significance of the substance P in the dorsal roots of the spinal cord]

1 reference

12 December 2020

Cholecystokinin CCK(B) receptor mRNA isoforms: expression in schizophrenic brains

1 reference

12 December 2020

Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia

1 reference

12 December 2020

Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment

1 reference

12 December 2020

The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls

1 reference

12 December 2020

Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response

1 reference

12 December 2020

Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment

1 reference

12 December 2020

Neuropeptide Y in frontal cortex is not altered in major depression

1 reference

12 December 2020

The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami

1 reference

12 December 2020

Vasopressin in depression

1 reference

12 December 2020

Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia

1 reference

12 December 2020

Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study

1 reference

12 December 2020

Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress

1 reference

12 December 2020

Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia

1 reference

12 December 2020

Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome

1 reference

12 December 2020

A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin in schizophrenia

1 reference

12 December 2020

A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH

1 reference

12 December 2020

Cerebrospinal fluid vasopressin--changes in depression

1 reference

12 December 2020

The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia

1 reference

12 December 2020

Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients

1 reference

12 December 2020

Antidepressants and hypothalamic-pituitary-adrenocortical regulation

1 reference

12 December 2020

Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach

1 reference

12 December 2020

Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function

1 reference

12 December 2020

Growth hormone (GH) response to GH-releasing hormone in depression

1 reference

12 December 2020

Vasopressin and oxytocin neurons of the human supraoptic and paraventricular nucleus: size changes in relation to age and sex.

1 reference

12 December 2020

Endorphins and schizophrenias. II. Trial treatment of schizophrenia with des-Tyr-gamma-endorphin (DT gamma E) (including a personal trial)

1 reference

12 December 2020

Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study

1 reference

12 December 2020

Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo

1 reference

12 December 2020

Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment

1 reference

12 December 2020

Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia.

1 reference

12 December 2020

Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression

1 reference

12 December 2020

Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls

1 reference

12 December 2020

CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin)

1 reference

12 December 2020

The functional neuroanatomy of corticotropin-releasing factor.

1 reference

12 December 2020

A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients

1 reference

12 December 2020

Reduction of plasma oxytocin levels in patients suffering from major depression.

1 reference

12 December 2020

No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study

1 reference

12 December 2020

Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls

1 reference

12 December 2020

Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects

1 reference

12 December 2020

Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia

1 reference

12 December 2020

Elevation of immunoreactive CSF TRH in depressed patients

1 reference

12 December 2020

Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia

1 reference

12 December 2020

Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia

1 reference

12 December 2020

Treatment of schizophrenia with a vasopressin analogue

1 reference

12 December 2020

Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression

1 reference

12 December 2020

Endorphins and schizophrenia

1 reference

12 December 2020

Vasopressin and oxytocin receptors in the central nervous system.

1 reference

12 December 2020

Cerebrospinal fluid neurophysins in affective illness and in schizophrenia

1 reference

12 December 2020

Cholecystokinin, dopamine and schizophrenia

1 reference

12 December 2020

Des-enkephalin-gamma-endorphin in the treatment of schizophrenia

1 reference

12 December 2020

Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients

1 reference

12 December 2020

Elevation of substance P-like peptides in the CSF of psychiatric patients

1 reference

12 December 2020

CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients

1 reference

12 December 2020

Hypothalamic-pituitary-adrenal axis and suicide

1 reference

12 December 2020

Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients

1 reference

12 December 2020

Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study

1 reference

12 December 2020

γ-Type Endorphins and Schizophrenia

1 reference

12 December 2020

Vasopressin function in depression and mania [proceedings]

1 reference

12 December 2020

Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders

1 reference

12 December 2020

Vasotocin effects in depressive patients with eating disorders

1 reference

12 December 2020

Substance P-like immunoreactivity in plasma of psychotic patients and effects of neuroleptics and electroconvulsive therapy

1 reference

12 December 2020

Neurotensin: perchance an endogenous neuroleptic?

1 reference

12 December 2020

Plasma arginine vasopressin and motor activity in major depression

1 reference

12 December 2020

Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment

1 reference

12 December 2020

Use of the dexamethasone suppression test in depression

1 reference

12 December 2020

Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression

1 reference

12 December 2020

Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study

1 reference

12 December 2020

Difference between evening and morning thyrotropin responses to protirelin in major depressive episode

1 reference

12 December 2020

(Des-Tyr1)-γ-endorphin in the treatment of schizophrenia

1 reference

12 December 2020

High-affinity interaction of (des-Tyrosyl)dynorphin A(2-17) with NMDA receptors.

1 reference

12 December 2020

Ceruletide for schizophrenia: a double-blind study

1 reference

12 December 2020

Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression

1 reference

12 December 2020

Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients

1 reference

12 December 2020

A high-dose, double-blind study of ceruletide in the treatment of schizophrenia

1 reference

12 December 2020

Somatostatin immunoreactivity in postmortem brain from depressed suicides

1 reference

12 December 2020

The Journal of Clinical Endocrinology and Metabolism

63

74

1325

T.D. Geracioti

1992

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

Zur Frage der zentralen �bertragung afferenter Impulse

3 January 2024

series ordinal

115

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

3 January 2024

Biological Psychiatry

123

19

877

F. Lotstra

1984

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

3 January 2024

Biological Psychiatry

139

15

283

C.B. Nemeroff

1980

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

3 January 2024

Biological Psychiatry

160

19

509

R. Rimon

1984

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

Ciba Foundation Symposium

3 January 2024

173

172

5

P.E. Sawchenko

1993

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

Journal of Pharmacology and Experimental Therapeutics

3 January 2024

182

291

760

Q. Tang

1999

1 reference

https://api.crossref.org/works/10.1080/10298420290031432

3 January 2024

Identifiers

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference